. Mean tumor volume evolution ± SD of different cases studied in this and previous work from the group. IR cases until euthanization day (n = 5, case C974 was not included because it was followed up until endpoint) are represented with black line; LR cases (n = 2) with red line; HR cases (n = 2) with green line and control cases (n = 32, in addition to the 4 control cases explored in this work, 28 additional cases from previous work from our group were added to confirm consistent evolution pattern by MRI follow-up) with purple line. Significant differences (p < 0.05) were observed for tumor volume evolution between IR cases and HR cases; and between LR cases and control cases. The TMZ administration period is not represented in the graph due to different schedules used in HR cases. See supplementary table 1 for euthanization days in each case. This graph is not representative of the overall survival of mice because mice were euthanized at specific time points to perform histopathological validation (i.e., it was not an endpoint study). Figure S2 . Mean ± SD evolution of body weight of mice studied by multi-slice MRSI (mouse weight at day of cell injection (day 0 p.i.) was considered 100%). IR cases are represented in black (C974 is not included in this graph because it was followed up until endpoint, and at that point it could be no longer classified as an IR case), LR cases are represented in red and HR cases are represented in green. The dashed blue line indicates the 20% weight reduction point. Significant differences (p < 0.05) in body weight evolution were observed between all groups.
. Mean tumor volume evolution ± SD of different cases studied in this and previous work from the group. IR cases until euthanization day (n = 5, case C974 was not included because it was followed up until endpoint) are represented with black line; LR cases (n = 2) with red line; HR cases (n = 2) with green line and control cases (n = 32, in addition to the 4 control cases explored in this work, 28 additional cases from previous work from our group were added to confirm consistent evolution pattern by MRI follow-up) with purple line. Significant differences (p < 0.05) were observed for tumor volume evolution between IR cases and HR cases; and between LR cases and control cases. The TMZ administration period is not represented in the graph due to different schedules used in HR cases. See supplementary table 1 for euthanization days in each case. This graph is not representative of the overall survival of mice because mice were euthanized at specific time points to perform histopathological validation (i.e., it was not an endpoint study). Figure S2 . Mean ± SD evolution of body weight of mice studied by multi-slice MRSI (mouse weight at day of cell injection (day 0 p.i.) was considered 100%). IR cases are represented in black (C974 is not included in this graph because it was followed up until endpoint, and at that point it could be no longer classified as an IR case), LR cases are represented in red and HR cases are represented in green. The dashed blue line indicates the 20% weight reduction point. Significant differences (p < 0.05) in body weight evolution were observed between all groups. Figure S3 . Graphical representation of the tumor volume evolution (in mm 3 , black line, left axis), and the percentage of responding "green" pixels obtained after NMF analysis of MRSI data acquired in the multi-slice set as in [1] (in %, green line, right axis). For chosen time points, the evolution of the nosological images obtained with the semisupervised source extraction system is shown in four columns of colour coded grids, superimposed to the T2w-MRI for each slice. The green shaded columns indicate TMZ administration periods. (A). Corresponds to the IR case C975, green pixels were observed first in grid 1 and a few in grid 2 at day 20 p.i. At day 23 p.i., green pixels were observed only in grid 2 and at day 26 p.i., green pixels were observed in grids 1 and 2 with a TRI = 40.3%. Tumor volume variation meeting criteria for 'stable disease' according to RECIST was observed from day 23 to 26 p.i. (B). Corresponds to the IR case C1023, green pixels were observed in grid 1 at days 18 and 21 p.i., at day 23 p.i. green pixels were observed in grids 1 and 2 (TRI = 35.8%), this TRI increase coincides with the possible beginning of a stable disease stage (volume increase with respect to preceding observation of 15.1%). (C). Corresponds to the IR case C1026, with an evolution similar to the C1023 case, green pixels were observed only in grid 1 at day 18 p.i. while green pixels were observed in grids 1 and 2 at days 21 and 23 p.i. (TRI = 38.9%, at day 23 p.i.). From day 21 to 23 p.i., the beginning of a stable disease stage was also observed.
Figure S4.
Comparison of responding/non responding spectral patterns with expansions in some differential zones with tentative metabolite assignment as in Figure 5 and Table 1 . (A) Prototypical patterns (sources) extracted from TMZ treated (green) and untreated (read) tumor-bearing mice as described in [1] . (B) Superimposition of average spectra from an untreated case (n = 44, red voxels, C1112 day 13 p.i., grid 2) and a treated case (n = 32, green voxels, C1108 day 29 p.i., grid 1). (C) Superimposition of average spectra from the zones classified either as non-responding (n = 35, red) or responding (n=26) from mouse C971, an IR case. ML, MM: mobile lipids + macromolecules; Ala, ML: alanine + mobile lipids; NAc/ML: N-acetyl containing compounds + mobile lipids; PUFA: polyunsaturated fatty acids in mobile lipids; Glx, glutamine + glutamate; Gly: glycine (glycine signal is also contributed by myoinositol, Ins); Lac: lactate. Tentative resonance assignment according to [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . an increase in such acellular spaces was observed in treated cases, the more TRI response classification, the more acellular spaces were observed. Boxplot features are the same as explained in Figure 9 . *: p < 0.05 with Mann-Whitney's U test. Figure S9 . TMZ administration schema with 3 therapy cycles with a 3-day interleave, as described previously by us [10] . The starting day of each cycle is marked with green arrows. The duration of each cycle (5 days for the first cycle, 2 days for second and third cycle) was the same for mice groups A and B. The cycle shown in this figure is the corresponding to group A. For group B, the starting day was adapted to tumor volume (see section 2.2 of the main manuscript). 
